DSP-2230

Last updated
DSP-2230
DSP-2230.svg
Clinical data
Routes of
administration 		By mouth
Identifiers
  • (2S)-2-{{#parsoidfragment:1}}3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide
CAS Number
UNII
ChEMBL
Chemical and physical data
Formula C20H20F3N5O2
Molar mass 419.408 g·mol−1
3D model (JSmol)
  • FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F
  • InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1
  • Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N

DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. [1] [2] As of June 2014, it is in phase I/phase II clinical trials. [1] [2]

Contents

See also

References

  1. 1 2 Martz L (2014). "Nav-i-gating antibodies for pain". Science-Business EXchange. 7 (23): 662. doi: 10.1038/scibx.2014.662 . ISSN   1945-3477.
  2. 1 2 Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi: 10.1016/j.bmcl.2014.06.038 . PMID   25060923.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.